TerminatedPHASE1, PHASE2NCT01384162

An Open Label, Safety and Tolerability Continuation Study of Intracerebroventricular Administration of sNN0029 to Patients With Amyotrophic Lateral Sclerosis

Studying Amyotrophic lateral sclerosis

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Newron Sweden AB
Principal Investigator
Wim Robberecht, MD, PhD
University Hospital Leuven, Department of Neurology
Intervention
sNN0029(drug)
Enrollment
15 enrolled
Eligibility
18-75 years · All sexes
Timeline
20092015

Study locations (1)

Collaborators

Medtronic · ICON Clinical Research

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT01384162 on ClinicalTrials.gov

Other trials for Amyotrophic lateral sclerosis

Additional recruiting or active studies for the same condition.

See all trials for Amyotrophic lateral sclerosis

← Back to all trials